Psychedelics are a “game changer” in depression care, according to William Blair, but the complicated treatment regimens mean ...
AbbVie ABBV reported encouraging fourth-quarter and full-year 2025 results last month. While the company’s immunology portfolio accounted for the bulk of revenue growth, its neuroscience franchise ...
March 5 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Johnson & Johnson's treatment for a type of ...
On Thursday, the U.S. Food and Drug Administration approved Johnson & Johnson‘s JNJ Tecvayli in combination with Darzalex Faspro for patients with relapsed or refractory multiple myeloma. The agency ...
Johnson & Johnson (NYSE:JNJ) is one of the best stocks that will always grow. Johnson & Johnson (NYSE:JNJ) announced on March 5 that the U.S. Food and Drug Administration (FDA) granted approval for ...
The FDA has approved Johnson & Johnson’s TECVAYLI plus DARZALEX FASPRO for the treatment of adults with relapsed or refractory multiple myeloma.
The approval was supported by data from the ongoing Phase III MajesTEC-3 study.
U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million in cash, cash equivalents and short ...
Copyright 2026 The Associated Press. All Rights Reserved. Copyright 2026 The Associated Press. All Rights Reserved. President Donald Trump listens as Dr. Marty Makary ...
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) said it has submitted a supplemental Biologics License Application to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results